In the light of the global pandemic, Lonza looks to be one of the beneficiaries with its deep knowledge in the production of biological molecules. The company had been selected quite early on by one of the mRNA vaccine frontrunners. Furthermore, health ingredients and nutrition supplements are facing higher demand in such times. Reported figures were stronger than expected and also beat consensus.
24 Jul 2020
Driving Pharma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Driving Pharma
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
24 Jul 2020 -
Author:
Martin Schnee -
Pages:
3
In the light of the global pandemic, Lonza looks to be one of the beneficiaries with its deep knowledge in the production of biological molecules. The company had been selected quite early on by one of the mRNA vaccine frontrunners. Furthermore, health ingredients and nutrition supplements are facing higher demand in such times. Reported figures were stronger than expected and also beat consensus.